Interobserver variability for retreatment indications after Ranibizumab loading doses in neovascular age-related macular degeneration

Acta Ophthalmologica

Volumn 90, Issue 1, 2012, Pages 49-55

  Framme, Carsten ^a   Panagakis, Georgios ^a   Walter, Andreas ^a   Gamulescu, Maria Andreea ^a   Herrmann, Wolfgang ^a   Helbig, Horst ^a  

^a University Eye Clinic Bern   (Switzerland)

Author keywords

age related macular degeneration; Anti VEGF; choroidal neovascularization; intravitreal injection; Lucentis; Ranibizumab; spectral domain optical coherence tomography

Indexed keywords

RANIBIZUMAB;

AGREEMENT RATE; HUMAN; KAPPA STATISTICS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OBSERVER VARIATION; OUTCOME ASSESSMENT; PATIENT INFORMATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETREATMENT; REVIEW; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; TREATMENT INDICATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTRAVITREAL INJECTIONS; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; RETINA; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84856525093     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.01940.x     Document Type: Review

References (21)

1. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, &, Noureddin BN, (2009): Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 148: 59-65.
2. Bressler NM, (2004): Age-related macular degeneration is the leading cause of blindness. JAMA 291: 1900-1901. (Pubitemid 38509505)
3. Bressler NM, Treatment of Age-related macular degeneration with photodynamic therapy (TAP) study group (2001): Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119: 198-207. (Pubitemid 32147926)
4. Brown DM, Kaiser PK, Michels M, et al., (2006): Ranibizumab versus Verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444. (Pubitemid 44511558)
5. Eye Disease Prevalence Research Group (2004): Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122: 564-572.
6. Framme C, Panagakis G, &, Birngruber R, (2010): Effects on choroidal neovascularizations after anti-VEGF upload using intravitreal Ranibizumab as determined by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 53: 1671-1676.
7. Golbaz I, Ahlers C, Schütze C, Stock G, Mylonas G, Prünte C, &, Schmidt-Erfurth U, (2009): Influence of antiangiogenetic therapy on retinal thickness values in age-related macular degeneration. Ophthalmologe 106: 1103-1110.
8. Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT, Walsh AC, &, Sadda SR, (2008): Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 49: 3115-3120.
9. Kiss CG, Geitzenauer W, Simader C, Gregori G, &, Schmidt-Erfurth U, (2009): Evaluation of ranibizumab-induced changes of high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 50: 2376-2383.
10. Lalwani GA, Rosenfeld PJ, Fung AE, et al., (2009): A variable-dosing regimen with intravitreal Ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 148: 43-58.
11. Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, &, Schmidt-Erfurth U, (2009): Effect of intravitreal bevacizumab (Avastin®) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmol (Epub ahead of print).
12. Neue Aspekte in der Therapie der neovaskulären altersbedingten Makuladegeneration (2009): Aktuelle Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands e.V(Stand März 2009). Ophthalmologe 106: 457-464.
13. Patel PJ, Chen FK, Ikeji F, &, Tufail A, (2009): Intersession repeatability of optical coherence tomography measures of retinal thickness in early age-related macular degeneration. Acta Ophthalmol (Epub ahead of print).
14. Regillo CD, Brown DM, Abraham P, et al., (2008): Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145: 239-248.
15. Rosenfeld PJ, Brown DM, Heier JS, et al., (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431. (Pubitemid 44511557)
16. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, &, Wolf-Schnurrbusch UEK, (2009): Effects of Ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 147: 831-837.
17. Sayanagi K, Sharma S, Yamamoto T, &, Kaiser P, (2009): Comparison of spectral-domain versus time-domain optical coherence in management of age-related macular degeneration with Ranibizumab. Ophthalmology 116: 947-955.
18. Schaal KB, Höh AE, Scheuerle A, Schütt F, &, Dithmar S, (2009): OCT-based re-injections for anti-VEGF-treatment for neovascular ARMD [German]. Ophthalmologe 106: 334-339.
19. Schneider U, Gelisken F, &, Inhoffen W, (2005): Natural course of occult choroidal neovascularization in age-related macular degeneration: development of classic lesions in fluorescein angiography. Acta Ophthalmol Scand 83: 141-147. (Pubitemid 40561820)
20. Spaide RF, (2009): The As-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol 148: 1-3.
21. Viera AJ, &, Garrett JM, (2005): Understanding interobserver agreement: the Kappa statistic. Fam Med 37: 360-363. (Pubitemid 40656185)